Q-omics provides the consensus-scored KDM8 profile across patient tissues and cancer cell-line models. KDM8 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, KDM8 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, KDM8 RNA expression shows 20,019 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight PAAD, LIHC, and ACC as cancer lineages where KDM8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KDM8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KDM8 survival associations across molecular data types. KDM8 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KDM8 RNA expression–survival associations across cancer types. High KDM8 expression shows unfavorable associations in LUSC, but favorable associations in PAAD, READ, HNSC, KIRP and LIHC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for KDM8 RNA expression.
This table summarizes KDM8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KDM8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KDM8 shows lower tumor expression in LIHC, THCA, LUSC, CHOL and KICH and higher tumor expression in KIRC. The LIHC box plot shows higher KDM8 RNA expression in normal versus tumor tissue (log2 FC = −2.510, t-test p < 0.001).
This table shows molecular features associated with KDM8 in patient tissues and cancer cell lines. In patient samples, KDM8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KDM8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
